Alternatively, the increased levels of hypermethylation within HLRCC tumors could be either more beneficial, necessary, or tolerable in conjunction with the other changes induced by FH mutation than with SDHB mutation, allowing for a greater enrichment of hypermethylation. The gene discussed is SDHB; the disease is hereditary leiomyomatosis and renal cell cancer.